Significantly, as our main conclusion, this work highlights that combining EGFR inhibitors and chemotherapeutic drugs enhanced the efficacy at cellular and molecular levels in two distinct breast cancer cell lines, which represents an important path towards expanding treatment options for TNBC in particular. This evidence concerns the gene EGFR and breast carcinoma.